Dosimetry: The next frontier

Sunday, March 5, 2023

8:30 AM – 10:00 AM

Location:Phoenix Convention Center, 228AB

CE: 1.5 Credits

Coordinator(s)

Shamar Young, MD

Professor
University of Arizona

Disclosure(s): Boston Scientific: Advisory Committee or Review Panel Member (Ongoing), Consultant (Ongoing), Speaking and Teaching (Ongoing); Galvanize Therapeutics: Consultant (Ongoing); Histosonics Inc: Consultant (Terminated); Mirada: Consultant (Ongoing); Varian: Consultant (Ongoing)
Nima Kokabi, MD

Associate Professor of Radiology
University of North Carolina - Chapel Hill

Disclosure(s): No financial relationships to disclose

Disclosure(s):

Shamar Young, MD: Boston Scientific: Advisory Committee or Review Panel Member (Ongoing), Consultant (Ongoing), Speaking and Teaching (Ongoing); Galvanize Therapeutics: Consultant (Ongoing); Histosonics Inc: Consultant (Terminated); Mirada: Consultant (Ongoing); Varian: Consultant (Ongoing)

Nima Kokabi, MD: No financial relationships to disclose

This session will review the advancements in dosimetry for radioembolization which have been made over the last several years. It will also discuss current challenges and future directions.

Learning Objectives:

To understand the current evidence on dose thresholds for hepatocellular carcinoma paitents undergoing transarterial radioembolization
To gain knowledge on what is known, and remains unknown, in regards to normal tissue toxicity
To understand available evidence on dose thresholds for non-HCC patients and areas requiring further investigation.

Presentations:

8:30 AM – 8:43 AM

Normal tissue dosing, a waist of time or integral treatment tool
Speaker: Shamar Young, MD – University of Arizona
8:43 AM – 8:56 AM

Y90 surrogates: Is Tc-MAA the best we can do?
Speaker: Nima Kokabi, MD – University of North Carolina - Chapel Hill
8:56 AM – 9:09 AM

Dosimetry in HCC: What do we know, what can we still learn
Speaker: Nima Kokabi, MD – University of North Carolina - Chapel Hill
Speaker: Shamar Young, MD – University of Arizona
9:09 AM – 9:22 AM

Dosimetry in mCRC: How do I maximize outcomes?
Speaker: Armeen Mahvash, MD – MD Anderson Cancer Center
9:22 AM – 9:35 AM

Dosimetry in cancers where data doesn't exist, what do I do?
Speaker: Siddharth Padia, MD, FSIR – UCLA
9:35 AM – 9:48 AM

Dosimetry: Future directions and areas of research focus.
Speaker: Beau Toskich, MD, FSIR – Mayo Clinic Jacksonville
9:48 AM – 10:00 AM

Q & A